Konecny et al., reported 37 % of primary ovarian cancer patients demonstrated Rb1 proficiency with low P16 expression with poor clinical outcome but were most likely to benefit from CDK4/6 inhibition [4]. This evidence concerns the gene CDK4 and ovarian cancer.